Bach Pharma, Inc. is a global leader in the development of revolutionary phthalazinedione-based therapeutics for the treatment of life-threatening neurodegenerative diseases. Their novel cytoprotective agent, GVT, shows promising anti-oxidant and anti-inflammatory properties, making it a potential treatment for serious diseases of the central nervous and immune systems associated with oxidative stress and inflammatory pathways.
Dedicated to improving patients' lives and reducing the cost of global healthcare, Bach Pharma aims to allow those suffering from neuroimmuno-degenerative illnesses access to GVT, helping them regain their quality of life. With ongoing research and FDA approvals, Bach Pharma is committed to creating a world free of diseases like GWI, ALS, Parkinson's, Alzheimer's, and other similar conditions.
Generated from the website